Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
REVIEW
Ruzhual K Man, Amaresh Gogikar, Ankita Nanda, Lakshmi Sai Niharika Janga, Hembashima G Sambe, Mohamed Yasir, Shivana Ramphall
Idiopathic pulmonary fibrosis (IPF), which shares a radiographic pattern with the usual interstitial pneumonia (UIP), is a specific form of chronic and progressive interstitial lung disorder resulting in persistent fibrosis and impaired lung function. Most of the patients suffer from dyspnea which adversely affects health-related quality of life (HRQOL). The underlying etiology of the disease is not yet understood, but research done on the subject reveals that aberrant repair mechanisms and dysregulated immune responses may be the cause...
February 2024: Curēus
#2
JOURNAL ARTICLE
Lisa Zickuhr, Eric Roberts, Tyler Daugherty, Amaad Rana, Hirva Joshi, Bruin Pollard, Jonathan Yu, Heather A Jones, Sarah Goglin
OBJECTIVE: In 2020, Strait and colleagues raised awareness that the clinical images in rheumatology educational materials underrepresent people with skin of color (P-SOC). Since then, publishers of rheumatology educational materials have focused on addressing this shortcoming. This study investigates the change in representation of P-SOC following Strait's review. METHODS: We used Strait's methods to collect images from commonly referenced rheumatology educational materials and categorized the skin tones within them as "light" or "dark...
March 18, 2024: Arthritis Care & Research
#3
EDITORIAL
Selwyn O Rogers, Richard P Wenzel
New England Journal of Medicine, Volume 390, Issue 5, Page 466-467, February 2024.
February 1, 2024: New England Journal of Medicine
#4
RANDOMIZED CONTROLLED TRIAL
Sheila Sprague, Gerard Slobogean, Jeffrey L Wells, Nathan N O'Hara, Lehana Thabane, C Daniel Mullins, Anthony D Harris, Amber Wood, Darius Viskontas, Kelly L Apostle, Robert V O'Toole, Manjari Joshi, Herman Johal, Jamal Al-Asiri, Robert A Hymes, Greg E Gaski, Holly T Pilson, Eben A Carroll, Sharon Babcock, Jason J Halvorson, Nicholas M Romeo, Christopher A Matson, Thomas F Higgins, Lucas S Marchand, Patrick F Bergin, John Morellato, Robert E Van Demark, G David Potter, I Leah Gitajn, Gerard Chang, Kevin D Phelps, Laurence B Kempton, Madhav Karunakar, Todd Jaeblon, Haley K Demyanovich, Christopher M Domes, Gabrielle R Kuhn, Rachel M Reilly, Mark J Gage, Michael J Weaver, Arvind G von Keudell, Marilyn Heng, Michael F McTague, Ahmad Alnasser, Samir Mehta, Derek J Donegan, Roman M Natoli, Jan Szatkowski, Alesha N Scott, Steven F Shannon, Kyle J Jeray, Stephanie L Tanner, Meir T Marmor, Amir Matityahu, Justin T Fowler, Sarah N Pierrie, Michael J Beltran, Cameron G Thomson, Carol A Lin, Charles N Moon, John A Scolaro, Arya Amirhekmat, Jordan Leonard, David Pogorzelski, Sofia Bzovsky, Diane Heels-Ansdell, Olivia P Szasz, Jodi L Gallant, Gregory J Della Rocca, Robert D Zura, Joan N Hebden, Joseph T Patterson, Christopher Lee, Lyndsay M O'Hara, Debra Marvel, Jana E Palmer, Jeff Friedrich, Jean-Claude G D'Alleyrand, Jessica C Rivera, Franca Mossuto, Gregory M Schrank, Gordon Guyatt, P J Devereaux, Mohit Bhandari
BACKGROUND: Studies evaluating surgical-site infection have had conflicting results with respect to the use of alcohol solutions containing iodine povacrylex or chlorhexidine gluconate as skin antisepsis before surgery to repair a fractured limb (i.e., an extremity fracture). METHODS: In a cluster-randomized, crossover trial at 25 hospitals in the United States and Canada, we randomly assigned hospitals to use a solution of 0.7% iodine povacrylex in 74% isopropyl alcohol (iodine group) or 2% chlorhexidine gluconate in 70% isopropyl alcohol (chlorhexidine group) as preoperative antisepsis for surgical procedures to repair extremity fractures...
February 1, 2024: New England Journal of Medicine
#5
JOURNAL ARTICLE
Nikita Patel, Hiral Shah
New England Journal of Medicine, Volume 390, Issue 3, Page 254-254, January 2024.
January 18, 2024: New England Journal of Medicine
#6
JOURNAL ARTICLE
Jimmy C T Lai, W K Claudia Wu, W S Agnes Chan, Louis H S Lau, Howard H W Leung
New England Journal of Medicine, Volume 389, Issue 25, Page 2377-2385, December 2023.
December 21, 2023: New England Journal of Medicine
#7
REVIEW
David R Stukus, Ruchi Gupta, Douglas Mack, Lianne Mandelbaum, Dareen Siri, Vivian Hernandez-Trujillo, Hugh A Sampson
WHAT IS THIS SUMMARY ABOUT?: This is a summary of an article published in The New England Journal of Medicine about the EPITOPE clinical study, which tested a skin patch called ViaskinTM Peanut 250 μg (micrograms) as a treatment option for peanut allergy in children aged 1 through 3 years. The patch is a form of epicutaneous immunotherapy (EPIT), which is a new approach to allergen immunotherapy that delivers a small amount of peanut protein to the immune system through the skin...
January 2024: Immunotherapy
#8
JOURNAL ARTICLE
Denis Čerimagić
Dear Editor, Although some of my colleagues may find this surprising, as a neurologist, I have noticed many connections between dermatology and neurology. Neurological and dermatological signs and symptoms are common in many clinical entities, especially in the so-called phakomatoses or neurocutaneous syndromes (Von Recklinghausen's disease type 1 and 2, Bourneville-Pringle syndrome, Sturge-Weber syndrome, Von Hippel-Lindau syndrome, Louis-Bar syndrome) (1). The terms "neurodermatitis" and "neurodermatology" also confirm the above...
November 2023: Acta Dermatovenerologica Croatica: ADC
#9
RANDOMIZED CONTROLLED TRIAL
Shawn G Kwatra, Gil Yosipovitch, Franz J Legat, Adam Reich, Carle Paul, Dagmar Simon, Luigi Naldi, Charles Lynde, Marjolein S De Bruin-Weller, Walter K Nahm, Maxwell Sauder, Rola Gharib, Sebastien Barbarot, Jacek C Szepietowski, Curdin Conrad, Alan Fleischer, Vivian T Laquer, Laurent Misery, Esther Serra-Baldrich, Hilde Lapeere, Faiz Ahmad, Zarif K Jabbar Lopez, Christophe Piketty, Sonja Ständer
BACKGROUND: Prurigo nodularis is a chronic, debilitating, and severely pruritic neuroimmunologic skin disease. Nemolizumab, an interleukin-31 receptor alpha antagonist, down-regulates key pathways in the pathogenesis of prurigo nodularis. METHODS: In this phase 3, double-blind, multicenter, randomized trial, we assigned adults with moderate-to-severe prurigo nodularis to receive an initial 60-mg dose of nemolizumab followed by subcutaneous injections of 30 mg or 60 mg (depending on baseline weight) every 4 weeks for 16 weeks or matching placebo...
October 26, 2023: New England Journal of Medicine
#10
RANDOMIZED CONTROLLED TRIAL
Marwan G Fakih, Lisa Salvatore, Taito Esaki, Dominik P Modest, David P Lopez-Bravo, Julien Taieb, Michalis V Karamouzis, Erika Ruiz-Garcia, Tae-Won Kim, Yasutoshi Kuboki, Fausto Meriggi, David Cunningham, Kun-Huei Yeh, Emily Chan, Joseph Chao, Yaneth Saportas, Qui Tran, Chiara Cremolini, Filippo Pietrantonio
BACKGROUND: KRAS G12C is a mutation that occurs in approximately 3 to 4% of patients with metastatic colorectal cancer. Monotherapy with KRAS G12C inhibitors has yielded only modest efficacy. Combining the KRAS G12C inhibitor sotorasib with panitumumab, an epidermal growth factor receptor (EGFR) inhibitor, may be an effective strategy. METHODS: In this phase 3, multicenter, open-label, randomized trial, we assigned patients with chemorefractory metastatic colorectal cancer with mutated KRAS G12C who had not received previous treatment with a KRAS G12C inhibitor to receive sotorasib at a dose of 960 mg once daily plus panitumumab (53 patients), sotorasib at a dose of 240 mg once daily plus panitumumab (53 patients), or the investigator's choice of trifluridine-tipiracil or regorafenib (standard care; 54 patients)...
December 7, 2023: New England Journal of Medicine
#11
REVIEW
Ajai Chari, Elham Askari, Jo Caers, Luciano J Costa, Brandi W Hilder, Amrita Krishnan, María-Victoria Mateos, Monique C Minnema, Albert Oriol, Kodandaram Pillarisetti, Niels W C J van de Donk, Paula Rodríguez-Otero
WHAT IS THIS SUMMARY ABOUT?: This plain language summary describes the results of a phase 1 research study (or clinical trial) called MonumenTAL-1 published in the New England Journal of Medicine in December 2022. A phase 1 study is an early clinical trial where researchers evaluate how safe a medicine is at different doses in a small number of people. In the MonumenTAL-1 study, researchers looked at a new medicine under development called talquetamab, for people living with multiple myeloma (a type of blood cancer) who did not respond (refractory), stopped responding (relapsed), or who had difficulty dealing with their previous treatments...
September 2023: Future Oncology
#12
JOURNAL ARTICLE
Yantong Wan, Junyi Shen, Yinghao Hong, Jinghua Liu, Tieliu Shi, Junwei Cai
BACKGROUND: Melanoma is a skin tumor with a high mortality rate, and early diagnosis and effective treatment are the key to reduce its mortality rate. Therefore, more and more attention has been paid for biomarker identification for early diagnosis, prognosis prediction and prognosis evaluation of melanoma. However, there is still a lack of a report that comprehensively and objectively evaluates the research status of melanoma biomarkers. Therefore, this study aims to intuitively analyze the research status and trend of melanoma biomarkers through the methods of bibliometrics and knowledge graph...
2023: Frontiers in Oncology
#13
JOURNAL ARTICLE
Jessica O'Neil, Stephen Kovach
New England Journal of Medicine, Volume 388, Issue 24, Page 2274-2274, June 2023.
June 15, 2023: New England Journal of Medicine
#14
REVIEW
Ashley Wysong
New England Journal of Medicine, Volume 388, Issue 24, Page 2262-2273, June 2023.
June 15, 2023: New England Journal of Medicine
#15
JOURNAL ARTICLE
Hratch Baghdassarian, Sarah A Blackstone, Owen S Clay, Rachael Philips, Brynja Matthiasardottir, Michele Nehrebecky, Vivian K Hua, Rachael McVicar, Yang Liu, Suzanne M Tucker, Davide Randazzo, Natalie Deuitch, Sofia Rosenzweig, Adam Mark, Roman Sasik, Kathleen M Fisch, Pallavi Pimpale Chavan, Elif Eren, Norman R Watts, Chi A Ma, Massimo Gadina, Daniella M Schwartz, Anwesha Sanyal, Giffin Werner, David R Murdock, Nobuyuki Horita, Shimul Chowdhury, David Dimmock, Kristen Jepsen, Elaine F Remmers, Raphaela Goldbach-Mansky, William A Gahl, John J O'Shea, Joshua D Milner, Nathan E Lewis, Johanna Chang, Daniel L Kastner, Kathryn Torok, Hirotsugu Oda, Christopher D Putnam, Lori Broderick
BACKGROUND: Disabling pansclerotic morphea (DPM) is a rare systemic inflammatory disorder, characterized by poor wound healing, fibrosis, cytopenias, hypogammaglobulinemia, and squamous-cell carcinoma. The cause is unknown, and mortality is high. METHODS: We evaluated four patients from three unrelated families with an autosomal dominant pattern of inheritance of DPM. Genomic sequencing independently identified three heterozygous variants in a specific region of the gene that encodes signal transducer and activator of transcription 4 ( STAT4 )...
June 15, 2023: New England Journal of Medicine
#16
REVIEW
Sung Kyung Cho, Thomas Vazquez, Victoria P Werth
INTRODUCTION: There are no U.S. Food and Drug Administration (FDA) approved therapies for cutaneous lupus erythematosus (CLE). Litifilimab is a monoclonal antibody against BDCA2, a plasmacytoid dendritic cell specific antigen, currently under investigation for systemic lupus erythematosus (SLE) and CLE. The LILAC study, published in the New England Journal of Medicine , is a phase II randomized controlled trial for CLE which demonstrated superiority of Litifilimab over placebo using a skin directed outcome measure...
May 6, 2023: Expert Opinion on Investigational Drugs
#17
RANDOMIZED CONTROLLED TRIAL
Manisha Balwani, Herbert L Bonkovsky, Cynthia Levy, Karl E Anderson, D Montgomery Bissell, Charles Parker, Fumihiro Takahashi, Robert J Desnick, Kirstine Belongie
BACKGROUND: Erythropoietic protoporphyria and X-linked protoporphyria are inborn errors of heme biosynthesis that cause elevated circulating levels of metal-free protoporphyrin and phototoxicity. Both disorders are characterized by excruciating phototoxic attacks after exposure to visible light. Dersimelagon is a new, orally administered, selective melanocortin 1 receptor agonist that increases levels of skin eumelanin. METHODS: We conducted a randomized, placebo-controlled, phase 2 trial to investigate the efficacy and safety of dersimelagon with respect to the time to onset and the severity of symptoms associated with sunlight exposure in patients with erythropoietic protoporphyria or X-linked protoporphyria...
April 13, 2023: New England Journal of Medicine
#18
RANDOMIZED CONTROLLED TRIAL
Jonathan I Silverberg, Emma Guttman-Yassky, Diamant Thaçi, Alan D Irvine, Linda Stein Gold, Andrew Blauvelt, Eric L Simpson, Chia-Yu Chu, Zhuqing Liu, Renata Gontijo Lima, Sreekumar G Pillai, Julien Seneschal
BACKGROUND: Lebrikizumab, a high-affinity IgG4 monoclonal antibody targeting interleukin-13, prevents the formation of the interleukin-4Rα-interleukin-13Rα1 heterodimer receptor signaling complex. METHODS: We conducted two identically designed, 52-week, randomized, double-blind, placebo-controlled, phase 3 trials; both trials included a 16-week induction period and a 36-week maintenance period. Eligible patients with moderate-to-severe atopic dermatitis (adults [≥18 years of age] and adolescents [12 to <18 years of age, weighing ≥40 kg]) were randomly assigned in a 2:1 ratio to receive either lebrikizumab at a dose of 250 mg (loading dose of 500 mg at baseline and week 2) or placebo, administered subcutaneously every 2 weeks...
March 23, 2023: New England Journal of Medicine
#19
EDITORIAL
David M Miller, Kevin S Emerick
New England Journal of Medicine, Volume 388, Issue 9, Page 844-846, March 2023.
March 2, 2023: New England Journal of Medicine
#20
RANDOMIZED CONTROLLED TRIAL
Nicholas C Allen, Andrew J Martin, Victoria A Snaidr, Renee Eggins, Alvin H Chong, Pablo Fernandéz-Peñas, Douglas Gin, Shireen Sidhu, Vanessa L Paddon, Leith A Banney, Adrian Lim, Edward Upjohn, Helmut Schaider, Aparna D Ganhewa, Jennifer Nguyen, Catriona A McKenzie, Saurabh Prakash, Catriona McLean, Alistair Lochhead, Jan Ibbetson, Andrew Dettrick, Anthony Landgren, Katherine J Allnutt, Clare Allison, Rachael B Davenport, Blake P Mumford, Brittany Wong, Brendan Stagg, Alexander Tedman, Hannah Gribbin, Harrison A Edwards, Nicholas De Rosa, Thomas Stewart, Brent J Doolan, Yonatan Kok, Kate Simpson, Zhi M Low, Tom Kovitwanichkanont, Richard A Scolyer, Haryana M Dhillon, Janette L Vardy, Steven J Chadban, David G Bowen, Andrew C Chen, Diona L Damian
BACKGROUND: Immunosuppressed organ-transplant recipients have an increased incidence of, and mortality from, skin cancer. Nicotinamide (vitamin B3 ) enhances the repair of ultraviolet (UV) radiation-induced DNA damage, reduces the cutaneous immunosuppressive effects of UV radiation, and reduces the incidence of keratinocyte cancers (including squamous-cell and basal-cell carcinomas) and actinic keratoses among high-risk immunocompetent patients. Whether oral nicotinamide is useful for skin-cancer chemoprevention in organ-transplant recipients is unclear...
March 2, 2023: New England Journal of Medicine
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
